Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients

Atherosclerosis

Volumn 120, Issue 1-2, 1996, Pages 241-244

  Bostom, Andrew G ^a   Shemin, Douglas ^b   Yoburn, David ^b   Fisher, Daniel H ^c   Nadeau, Marie R ^a   Selhub, Jacob ^a  

^a TUFTS UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

Hyperhomocysteinemia; N acetylcysteine; Renal failure; Treatment

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINURIA; HYPERHOMOCYSTINURIA; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MALE; NEPHROSCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030040525     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05705-6     Document Type: Article

References (17)

1. Maiorca R, Cancarini GC, Brunori G, Camerini C, Manili L. Morbidity and mortality of CAPD and hemodialysis. Kidney Int 1993;43:S-4.
2. Parfrey PS, Harnett JD. Long term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 1994;23: 311.
3. Selhub J, Jacques PF, Bostom AG et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 1995; 332:286.
4. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullman D. A prospective study of plasma homocyst(e)ine and the risk of myocardial infarction in US physicians. J Am Med Assoc 1992;268:877.
5. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704.
6. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case control study. Atherosclerosis 1995;114:93.
7. Arnadottir M, Brattstrom LA, Simonsen O et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993;40:236.
8. Janssen MJ FM, Stehouwer CDA, van den Berg M, van der Meulen J, Boers GHJ, Donker AJM. Folic acid lowers elevated homocysteine levels in chronic dialysis patients. J Am Soc Nephrol 1993;4:250 (abstract 86P).
9. Guldener C, Janssen MJFM, van den Berg M, Stiuwher CDA, Donker AJM. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients. Perit Dial Int 1994;14 (Suppl 1):S-26 (abstract).
10. Bostom AG, Shemin D, Nadeau MR, Shih V, Stabler SP, Allen RH, Selhub J. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 1995;113:129.
11. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230.
12. Huttberg B, Andersson A, Masson P, Larson M, Tunek A. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest 1994;54:417.
13. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmocokinet 1991;20:123.
14. Bennett WM. Drug prescribing in renal failure: dosing guidelines for adults. Philadelphia, PA: American College of Physicians, 1991;150.
15. Bostom AG, Brosnan JT, Hall B, Nadeau MR, Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59.
16. Bostom AG, Yanek L, Hume AL et al. High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease. Atherosclerosis 1994;111:267.
17. Bostom AG, Shemin D, Lapane KL et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int (in press).